Overview

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.
Treatments:
Viloxazine